Evaluation of the Aptima HBV Quant Assay Compared to Abbott RealTime M2000 HBV Quant Assay and Procleix Ultrio Plus dHBV Assay in Plasma Samples-Reference-Cited by-同舟云学术

Evaluation of the Aptima HBV Quant Assay Compared to Abbott RealTime M2000 HBV Quant Assay and Procleix Ultrio Plus dHBV Assay in Plasma Samples

Published:2022-08-31 Issue:4 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Yan Ying¹²,Chang Le¹²,Ji Huimin¹²,Han Yang³,Wang Lunan¹²⁴^ORCID

Affiliation:

1. National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing, P. R. China

2. Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, P. R. China

3. Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China

4. Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P. R. China

Abstract

The Aptima HBV Quant assay (Hologic Inc., San Diego, CA, USA) is a dual-target real-time transcription-mediated amplification (RT-TMA) assay. This study aims to evaluate whether this assay is suitable for HBV DNA detection.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01761-22

Reference26 articles.

1. World Health Organization. 2017. Global hepatitis report. World Health Organization Geneva Switzerland.

2. World Health Organization. 2018. Hepatitis B. World Health Organization Geneva Switzerland. https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b.

3. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

4. The guidelines of prevention and treatment for chronic hepatitis B (2019 version);Chinese Society of Infectious Diseases;Zhonghua Gan Zang Bing Za Zhi,2019

5. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection